- Home
- QUMS vs MGNX Comparison
QUMS vs MGNX Comparison
Compare QUMS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QUMS | MGNX |
|---|---|---|
| Founded | 2024 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.2M | 115.8M |
| IPO Year | 2025 | 2013 |
Fundamental Metrics
Financial Performance| Metric | QUMS | MGNX |
|---|---|---|
| Price | $10.06 | $1.81 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 17.5K | ★ 955.6K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $127,626,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.92 | $0.99 |
| 52 Week High | $10.23 | $3.00 |
Technical Indicators
Market Signals| Indicator | QUMS | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 69.28 | 49.06 |
| Support Level | $10.05 | $1.66 |
| Resistance Level | $10.08 | $1.97 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 100.00 | 29.58 |
Price Performance
Historical ComparisonAbout QUMS Quantumsphere Acquisition Corp. Ordinary Shares
Quantumsphere Acquisition Corp is a newly organized blank check company.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.